TUKYSA Resources and Support
Take a look at the resources and support that are available to help you throughout treatment.
Is your guide to treatment and what you can expect from TUKYSA, including possible side effects
TUKYSA Treatment Tracker
Helps you keep track of your dosing plan and take notes about how you are feeling
TUKYSA Treatment Tracker Calendar Pages
Use these additional calendar pages to help you stay on your dosing plan
Frequently Asked Questions
Get answers to frequently asked questions (FAQs) about TUKYSA.
What is TUKYSA?
TUKYSA is a prescription medicine used with the medicines trastuzumab and capecitabine to treat adults with human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and who have received one or more anti-HER2 breast cancer treatments. It is not known if TUKYSA is safe and effective in children. Learn more about TUKYSA.
Could TUKYSA be right for me?
TUKYSA was studied in 612 people with HER2+ metastatic breast cancer that had spread (metastasized) to other parts of the body in a clinical trial called HER2CLIMB. These people had been treated before with HERCEPTIN® (trastuzumab), PERJETA® (pertuzumab), and KADCYLA® (trastuzumab emtansine).
In HER2CLIMB, people were either given:
- TUKYSA + trastuzumab + XELODA® (capecitabine)
- Trastuzumab + capecitabine alone
What are the most common side effects seen with TUKYSA?
The most common side effects with TUKYSA:
- rash, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet
- increased liver function blood tests
- mouth sores (stomatitis)
- decreased appetite
- stomach-area (abdomen) pain
- a low number of red blood cells (anemia)
These are not all the possible side effects of TUKYSA, and you may also get side effects from the other medicines taken with TUKYSA.
Talk to your healthcare provider about any side effects that bother you or do not go away. Learn more about possible side effects of treatment.
Has TUKYSA been evaluated in people with HER2+ metastatic breast cancer that has spread to the brain?
Yes. Nearly half of all people in HER2CLIMB—48% (291 out of 612)—had brain metastases. This included people with untreated and treated brain metastases that were stable or progressing since their last treatment. Learn more about treatment with TUKYSA.
Do I need tests with TUKYSA?
Your healthcare provider will test your blood to check your liver function before and every 3 weeks during treatment with TUKYSA, or as needed. These tests may be performed when you go in for your trastuzumab treatment. Based on the test results, your healthcare provider may adjust your dose, or temporarily or permanently stop treatment with TUKYSA.
If you are a female who can become pregnant, your healthcare provider will do a pregnancy test before starting TUKYSA.
There are many local, community, and national advocacy organizations available to help support people with breast cancer and their families. They each offer a range of services, including education, counseling, and financial assistance to help pay for the cost of treatment. There are also groups that offer legal services and employment advice.
Please note that the information that follows has been provided by each of the listed organizations. Seattle Genetics is not responsible for their content, and inclusion on this website is not intended as an endorsement of the organization or the services offered.
FORCE (Facing Our Risk of Cancer Empowered)
Living Beyond Breast Cancer (LBBC)
Sisters Network® Inc. (SNI)
Young Survival Coalition (YSC)
Cancer Support Community
Susan G. Komen
For additional resources that educate and support metastatic breast cancer patients, please visit the Metastatic Breast Cancer Alliance to learn about their member network of breast cancer organizations.